Zosano Pharma, Inc. To Present Positive Phase 2 Results Of Its Transdermal Patch For Osteoporosis

Main Category: Bones / Orthopedics
Article Date: 02 Apr 2009 - 3:00 PDT

email to a friend   printer friendly   opinions  

Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that an abstract detailing results of its Phase 2 study of ZP-PTH, a proprietary transdermal patch formulation of parathyroid hormone (PTH) for the treatment of established osteoporosis will be presented as a poster at the 8th International Symposium on Osteoporosis in Washington D.C.

The study results, titled "Rapid Pulse Transdermal Delivery of PTH (1-34) (ZP-PTH) is Effective in Increasing Bone Mineral Density of the Lumbar Spine and Hip in Postmenopausal Women with Osteoporosis" will be presented on Saturday, April 4, 2009, 9:45 a.m. Dr. Felicia Cosman, medical director of the clinical research center at Helen Hayes Hospital in West Haverstraw, New York, will make the presentation on behalf of the study's participating investigators.

About Zosano Pharma, Inc.

Zosano Pharma, Inc. is a privately held pharmaceutical company developing products for the treatment of osteoporosis, chemotherapy induced neutropenia and anemia associated with chronic kidney disease, using its novel transdermal delivery technology. Its lead clinical program, the ZP-PTH rapid delivery patch for the treatment of osteoporosis, is being developed as an alternative to daily injections. Zosano's transdermal delivery technology is capable of delivering peptides, proteins, small molecules and vaccines by permeating the skin's outer layer and ensuring significant therapeutic effect. This proven proprietary technology offers several key benefits, including efficacy and safety comparable to approved injectables, needle-free delivery, a self-administered patch, rapid onset of action and room temperature storage. Zosano's transdermal delivery technology has been clinically tested in over 400 patients with four different peptides and a vaccine. Zosano aims to develop products both independently and through strategic licensing and co-development arrangements. Founded in 2006 as an ALZA Corporation spin-out led by Nomura Phase4 Ventures, Zosano is funded by New Enterprise Associates, Nomura Phase4 Ventures, HBM BioVentures and ProQuest Investments. For more information, please visit http://www.zosanopharma.com.

Source
Zosano Pharma, Inc.

• Additional
• References
• Citations